


# 5<sup>th</sup> ESPT CONGRESS

PRECISION MEDICINE AND PERSONALISED HEALTH

SEVILLE, SPAIN

2019  
October  
16-18



European Society for Pharmacogenomics  
and Personalised Therapy



In collaboration with the  
Spanish Society of Pharmacogenomics  
and Pharmacogenomics (SEFF)

[www.2019esptcongress.eu](http://www.2019esptcongress.eu)

UNDER THE AUSPICES OF:

The logo for the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). It consists of the letters 'E', 'F', 'L', and 'M' in a stylized, blue, sans-serif font. The 'E' and 'F' are connected at the top, and the 'L' and 'M' are connected at the top. A small orange dot is positioned below the 'M'.

EUROPEAN FEDERATION OF CLINICAL CHEMISTRY  
AND LABORATORY MEDICINE

The logo for the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). It features the letters 'IFCC' in a bold, blue, sans-serif font. The 'I' is stylized with a vertical line extending downwards.

*International Federation  
of Clinical Chemistry  
and Laboratory Medicine*



SOCIETÀ ITALIANA DI FARMACOLOGIA

## WELCOME

Dear participant,

we are very pleased to welcome you here at the 5th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT 2019) in Seville, Spain.

A meeting bringing together leading international scientists and healthcare professionals who are actively working in the fields of Pharmacogenomics and Personalised Therapy. After successful events in the previous years (Catania 2017, Budapest 2015, Lisbon 2013, Bled 2011), we are very happy to have our 2019 meeting here in Spain, on this occasion in collaboration with the Spanish Society for Pharmacogenetics and Pharmacogenomics (SEFF). As ESPT, we are very grateful for this hospitality!

The theme of the ESPT 2019 congress is Precision Medicine and Personalised Health, and the program we have put together is, to our hoping, interesting and challenging for you. It is addressing the latest developments in the field of pharmacogenetics/pharmacogenomics, including liquid biopsy/cell free DNA as an fast upcoming approach to guide drug therapy. We are proud to include in our congress keynote speakers such as Prof. Dr. Sir Munir Pirmohamed, Prof. Dr. Ingolf Cascorbi, Dr. Lili Milani, Prof. Dr. Wolfgang Sadee, Prof. Dr. Daniel Mueller, Prof. Dr. Mike Caulfield, Prof. Dr. Klaus Pantel and many other excellent speakers. In addition, we have 100 posters with the latest results of ongoing research from mostly ambitious young scientists! Please take the opportunity to interact and discuss these latest findings with the poster presenters during the breaks. On Friday, the poster committee will hand out the award for the best poster contribution.

A special word of welcome and thanks to our sponsors, who have enabled us to have this meeting here. I am confident that you as a participant will enjoy the opportunity to interact with them, to obtain the latest information on technical as well as software developments.

As ESPT and SEFF Board, we hope that you will enjoy your stay in Seville. Enjoy your congress!

Kindest regards,

*Prof. Dr. Miquel Taron – President SEFF*

*Dr. Cristina Rodríguez-Antona – Secretary SEFF*

*Prof. Dr. Adrián Llerena – Vicepresident SEFF, Board ESPT*

*Prof. Dr. Ron van Schaik – President ESPT*



## ORGANIZING COMMITTEE

Miquel Taron  
*(University of Seville, President SEFF)*

Cristina Rodriguez-Antona  
*(CNIO, Madrid)*

Adrián Llerena  
*(University of Extremadura, Badajoz)*

Ron van Schaik  
*(Erasmus MC Rotterdam, President ESPT)*

## ESPT BOARD

Ron H.N. van Schaik  
*(President)*

Vangelis G. Manolopoulos  
*(President Elect)*

Maurizio Simmaco  
*(Treasurer)*

Sanja Stanković  
*(General Secretary)*

Marc Ansari  
*(Board Member)*

Peter Jacobs  
*(Board Member)*

Adrian Llerena  
*(Board Member)*

Janja Marc  
*(Board Member)*

Ingolf Cascorbi  
*(Board Member)*

Csilla Sipeky  
*(Board Member)*

Sophie Visvikis-Siest  
*(Board Member)*

## SPEAKERS

Alonso Sanchez Angel, Biomedical Research Center of Navarre, Pamplona, Spain  
Ansari Marc, University of Geneva, Switzerland  
Brunet Mercè, Hospital Clínic of Barcelona, Spain  
Carracedo Alvarez Angel Maria, University of Santiago de Compostela, Spain  
Cascorbi Ingolf, University of Kiel, Germany  
Caulfield Mark, William Harvey Heart Centre, University of London, UK  
Daly Ann K., Newcastle University, UK  
Danesi Romano, University of Pisa, Italy  
de la Haba Juan, Hospital Reina Sofia, Cordoba, Spain  
del Re Marzia, University Hospital of Pisa, Italy  
Dopazo Joaquin, Clinical Bioinformatics Area, FPS, Hospital Virgen del Rocio, Seville, Spain  
Gurwitz David, Tel Aviv University, Israel  
Henricks Linda M., Leiden University Medical Centre, The Netherlands  
Hachad Houda, Translational Software, Bellevue, WA, United States  
Huezo-Diaz Patricia, University of Geneva, Switzerland  
Ingelman-Sundberg Magnus, Karolinska Institutet, Stockholm, Sweden  
Kasper Dagmar, Agena Bioscience, Hamburg, Germany  
Lamy Pierre-Jean, Imagenome, Montpellier, France  
Lianidou Evi, University of Athens, Greece  
Llerena Adrián, University of Extremadura, Badajoz, Spain  
Lloberas Nuria, Bellvitge Biomedical Research Institute of Barcelona, Spain  
Manolopoulos Vangelis, University of Thrace, Alexandroupolis, Greece  
Milani Lili, University of Tartu, Estonia  
Mueller Daniel, Centre for Addiction and Mental Health of Toronto, Canada  
Niemi Mikko, University of Helsinki, Finland  
Nofziger Charity, PharmGenetix Gmbh, Salzburg, Austria  
Oellerich Michael, University of Göttingen, Germany  
Oram Richard, Institute of Biomedical & Clinical Science, University of Exeter Medical School, UK  
Pantel Klaus, University Medical Center Hamburg-Eppendorf, Germany  
Patrinos George, University of Patras, Greece  
Paulmichl Markus, Humanomed Center Althofen, Austria  
Pearson Ewan, University of Dundee, Scotland, UK  
Pirmohamed Munir, University of Liverpool, UK  
Rodríguez-Antona Cristina, National Centre for Oncological Research, Madrid Spain  
Sabater Ana, Eugenomic, Barcelona, Spain  
Sadee Wolfgang, The Ohio State University, Columbus, USA  
Schwab Matthias, Institute of Clinical Pharmacology Stuttgart, Germany  
Serrano María Jose, University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain  
Shaman Jeff, Coriell Life Sciences, Philadelphia, USA  
Simmaco Maurizio, University La Sapienza, Rome, Italy  
Sipeky Csilla, University of Turku, Finland  
Suarez-Kurtz Guilherme, Brazilian National Cancer Institute, Brazil  
Taron Miquel, Synlab, Madrid, Spain  
van Schaik Ron, Erasmus MC, Rotterdam, The Netherlands  
Vanoni Simone, Anif/Niederalm, Austria

# SCIENTIFIC PROGRAMME

WEDNESDAY **16<sup>th</sup> October**

08:30 Registration  
09:30 Opening: *Ron van Schaik* (ESPT President) - *Miquel Taron* (SEFF President)

## **SESSION 1 - PHARMACOGENETICS OVERVIEW**

*Chairs: Ron van Schaik, Miquel Taron*

09:45 Key note lecture - Pharmacogenetics of cutaneous adverse drug reactions - *Sir Munir Pirmohamed*  
10:15 Key note lecture - Pharmacogenetics of drug induced liver injury - *Ann Daly*  
10:45 Key note lecture - An initiative for early drug discovery with a pharmacogenomic perspective from Galicia - *Angel Carracedo*

11:15 Coffee Break

## **SESSION 2 - PSYCHIATRY**

*Chairs: Adrian Llerena, David Gurwitz*

11:45 Towards the implementation of pharmacogenomics in psychiatry - *Daniel Mueller*  
12:10 Genomic biomarkers for the efficacy of oxytocin in autism spectrum disorder - *David Gurwitz*  
12:35 New Pharmacogenetics software gNomic and drug interactions - *Ana Sabater*  
13:00 Lunch Break and Poster Visits

## **SESSION 3 - CYP2D6 GENOTYPING**

*Chairs: Magnus Ingelman-Sundberg, Urs Meyer*

14:30 Unraveling CYP2D6 genotyping: the optimal strategy - *Charity Nofziger*  
14:55 Functional characterization of known and unknown CYP2D6 variants using a cell-based in vitro system - *Simone Vanoni*

15:35 **INDUSTRY SPONSORED SESSION**      **AGENA BioSciences**  
Aspects of Molecular Analysis with Liquid Biopsy - *Dagmar Kasper*  
Liquid biopsy to personalize lung cancer treatment: overcoming the challenges  
*Pierre-Jean Lamy*

16:15 Coffee Break

## **SESSION 4 - ONCOLOGY**

*Chairs: Cristina Rodriguez-Antona, Csilla Sipeky*

16:45 Personalizing taxane treatment: from genetic variants to concomitant medication  
*Cristina Rodriguez-Antona*

- 17:10 Update on *DPYD* testing for safer fluoropyrimidine therapy - *Linda Henricks*  
17:35 PGx and tamoxifen breast cancer: an update - *Matthias Schwab*  
18:00 Personalised medicine of prostate cancer: impact of genomic biomarkers - *Csilla Sipeky*
- 18:30 OPENING RECEPTION

## THURSDAY 17<sup>th</sup> October

### SESSION 5 - LIQUID BIOPSY & CANCER

*Chairs: Romano Danesi, Janja Marc*

- 08:30 Key note lecture - Liquid biopsy: a new diagnostic concept in oncology - *Klaus Pantel*  
09:05 EGFR and lung cancer - *Romano Danesi*  
09:30 Circulating predictive biomarker of response to immunotherapy - *Marzia del Re*  
09:55 Molecular characterization of Circulating Tumor Cells: an update on technologies and clinical potential - *Evi Lianidou*
- 10:20 Coffee Break

### SESSION 6 - LIQUID BIOPSY & TRANSPLANTATION

*Chairs: Mercè Brunet, Maurizio Simmaco*

- 10:50 Graft-derived cell-free DNA as a marker for detection of rejection and graft injury after solid organ transplantation - *Michael Oellerich*  
11:15 Pharmacogenetics for guiding solid organ transplantation therapy: the BAROTAC study  
*Nuria Lloberas*  
11:40 Using Therapeutic Drug Monitoring in optimizing tacrolimus-personalized therapy and patient care in solid organ transplantation: the IATDMCT Consensus Report - *Mercè Brunet*
- 12:05 **INDUSTRY SPONSORED SESSION**      **Thermo Fisher**  
Outcomes from large population PGx testing - *Jeff Shaman*

- 12:50 Lunch Break and Poster Visits

### SESSION 7 - BIOBANK INITIATIVES, REGULATORY ASPECTS

*Chairs: Vangelis Manolopoulos, Luis Lopez*

- 14:00 The UK 100,000 Genomes Project: transforming health initiative - *Sir Mark Caulfield*  
14:30 Personalised Medicine based on common and rare genetic variants in Estonia - *Lili Milani*  
14:55 Regulatory aspects regarding implementation of PGx: SmPC information and EMA considerations - *Markus Paulmichl*  
15:20 What is the Foundation Medicine contribution in Precision Medicine? - *Juan de la Haba*

15:45 Coffee Break

### **SESSION 8 - PGx GENES**

*Chairs: Ingolf Cascorbi, Anna Gonzalez-Neira*

16:15 CYP3A genotyping - worth to consider it clinically? - *Ingolf Cascorbi*

16:40 The role of rare genetic variants for interindividual differences in drug metabolism, toxicity and response - *Magnus Ingelman-Sundberg*

17:05 Interindividual variability of CYP2D6, CYP3A4 and CYP7A1: underlying causes and clinical implications - *Wolfgang Sadee*

17:30 Implementing clinical pharmacogenetic programs: perspectives from a service provider  
*Houda Hachad*

18:00 ESPT GENERAL ASSEMBLY until 19:30

19:00 SEFF GENERAL ASSEMBLY

20:00 SEFF 1<sup>st</sup> Pharmacogenetic Proficiency Testing Accreditations

21:00 CONGRESS DINNER

## FRIDAY **18<sup>th</sup> October**

### **SESSION 9 - PGx AND PERSONALIZED MEDICINE CLINICAL IMPLEMENTATION INITIATIVES IN SPAIN**

*Chairs: Maria Jesus Arranz, Salvador Aliño*

09:00 MedeA: A global Implementation initiative of Personalized Medicine in a Public Health Care Service based on e-health - *Adrián Llerena*

09:25 Bioinformatics and the Andalusian initiative for personalized medicine - *Joaquin Dopazo*

09:50 Innovative purchase in Andalusia for liquid biopsy - *Maria Jose Serrano*

10:15 NAGEN: Proyecto Genoma 1000 Navarra - *Angel Alonso Sánchez*

10:40 Coffee Break

### **SESSION 10 - ESPT RESEARCH GROUPS**

*Chairs: Marc Ansari, Sofia Siest*

11:10 PGx and drug transporters - *Mikko Niemi*

11:35 What is the impact of pharmacogenomic to predict Sinusoidal obstructive syndrome in pediatric Stem cell transplantation - *Marc Ansari, Patricia Huezco-Diaz*

12:00 PGx in diabetes care - *Ewan Pearson*

12:25 Pharmacogenetics and personalised medicine in anticoagulation: latest developments -  
*Vangelis Manolopoulos*



12:45 Lunch Break and POSTER AWARDS

### **SESSION 11 - FUTURE PERSPECTIVES**

*Chairs: Sanja Stankovic, Francisco Abad*

- 14:00 Prediction and classification of type 1 diabetes using genetic risk scores - *Richard Oram*
- 14:25 Implementation of Pharmacogenomics in Europe: The U-PGx project - *George Patrinos*
- 14:50 Pharmacogenomic Implications of Population Admixture in Latin America  
*Guilherme Suarez-Kurtz*
- 15:15 The microbiome and response to drugs - *Maurizio Simmaco*
- 15:40 Discussion and final remarks - *Miquel Taron, Ron van Schaik*
- 16:00 END - Farewell Drinks

## **CLOSED MEETINGS**

### **WEDNESDAY 16<sup>th</sup> OCTOBER**

- 13:30 ESPT Board Meeting  
Alanda Room - until 15:30

### **THURSDAY 17<sup>th</sup> OCTOBER**


- 11:00 ESPT National Societies Meeting  
Alanda Room - until 12:00

### **FRIDAY 18<sup>th</sup> OCTOBER**

- 09:00 ESPT Corporate Members Meeting  
Alanda Room - until 10:00



# Scalable Pharmacogenetic Testing



With the MassARRAY® System  
from Agena Bioscience

Whether you're just getting started or growing an existing testing program, Agena Bioscience has the PGx solutions to make you successful. Get up and running quickly with the content you need. Process from one to thousands of samples a day without excessive reagent waste or cost. Easily update content to meet changing needs.

## Maximize Efficiency, Minimize Cost



### COMPREHENSIVE DETECTION

Genotyping & CNV detection on the same run.



### ROBUST PERFORMANCE

Accurate results, no need for duplicate samples.



### COST EFFECTIVE

Affordable upfront costs without excessive failures or waste.



For Research Use Only. Not for use in diagnostic procedures.

[agenabio.com](http://agenabio.com)

MassARRAY is a registered trademark  
of Agena Bioscience, Inc. GEN0022.01

## POSTERS

### CARDIOLOGY

**001**

COMPREHENSIVE ANALYSIS IDENTIFIES UGT1A3 VARIANTS AS MAJOR DETERMINANTS OF TELMISARTAN PHARMACOKINETICS

*[Hirvensalo Päivi](#), [Tornio Aleks](#), [Neuvonen Mikko](#), [Tapaninen Tuija](#), [Paile-Hyvärinen Maria](#), [Backman Janne](#), [Niemi Mikko](#)*

**002**

EFFECT OF GENE-DRUG INTERACTIONS LINKED TO CLOPIDOGREL AND CILOSTAZOL ON PLATELET REACTIVITY AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE

*[Duconge Jorge](#), [Hernandez-Suarez Dagmar F.](#), [Nunez Hector](#), [Melin Kyle](#)*

**003**

MACHINE LEARNING ALGORITHM FOR PREDICTING WARFARIN DOSES IN CARIBBEAN HISPANICS USING PHARMACOGENETIC DATA

*[Roche-Lima Abiel](#), [Feliu-Maldonado Roberto](#), [Roman-Santiago Adalis](#), [Rodríguez-Maldonado Jovaniel](#), [Nieves Brenda](#), [Carrasquillo Kelvin](#), [Duconge Jorge](#)*

**004**

NOVEL MICRORNAS ASSOCIATED WITH ADVANCED HUMAN ATHEROSCLEROTIC LESIONS - POTENTIAL BIOMARKERS AND THERAPEUTIC TARGETS

*[Manea Simona-Adriana](#), [Vlad Mihaela-Loredana](#), [Lazar Alexandra-Gela](#), [Cosac Monica-Teodora](#), [Muresian Horia](#), [Simionescu Maya](#), [Manea Adrian](#)*

**005**

THE ROLE OF PHARMACOGENETICS IN PRECISION MEDICINE: REINTRODUCTION OF ANTICOAGULANT THERAPY FOLLOWING INTRACRANIAL HEMORRHAGE

*[Šimičević Livija](#), [Vrkic Kirhmajer Majda](#), [Cohen Herak Desiree](#), [Ganoci Lana](#), [Bozina Tamara](#), [Bozina Nada](#)*

### CLINICAL IMPLEMENTATION INITIATIVES

**006**

FREQUENCIES OF PHARMACOGENETIC VARIANTS AND PREVALENCE OF PHARMACOGENETICALLY RELEVANT MEDICATIONS IN FINNISH UNIVERSITY HOSPITAL PATIENTS

*[Litonius Kaisa](#), [Kristiansson Kati](#), [Tarkiainen Katriina](#), [Ukkola-Vuoti Liisa](#), [Orpana Arto](#), [Lindstedt Mats](#), [Nyrönen Tommi](#), [Perola Markus](#), [Niemi Mikko](#)*

**007**

PILOT STUDY TO EVALUATE THE CLINICAL IMPLEMENTATION OF PHARMACOGENETIC ANALYSIS IN ORGAN TRANSPLANTATION

*[Herrero María José](#), [Sendra Luis](#), [Olivera Gladys](#), [Cervera José Vicente](#), [Montoro Juan](#), [Piñana José Luis](#), [Sanz Jaime](#), [Montalvá Eva](#), [López-Andújar Rafael](#), [Sales Gabriel](#), [Almenar Luis](#), [Hernandez Julio](#), [Aliño Salvador Francisco](#)*

**008**

## THE DUTCH EVIDENCE-BASED PHARMACOGENETIC GUIDELINES: CURRENT STATUS AND IMPLEMENTATION

*Nijenhuis Marga, Crommentuijn-van Rhenen Mandy H., de Boer-Veeger Nienke J., Buunk Anne Marie, Houwink Elisa J.F., Mulder Hans, Rongen Gerard A., van Schaik Ron H.N., Guchelaar Henk-Jan, Swen Jesse J., van der Weide Jan, Wilffert Bob, Deneer Vera H.M.*

**009**

## THE EFFICIENCY OF PPI USE IN TURKISH PATIENTS: CYP2C19 PHARMACOGENETIC TESTING

*Susleyici Belgin, Cevik Mehtap, Karaalp Atila, Yurdakul Selen, Canbolat Ismail Polat, Gunduz Hakan, Ceyhan Berrin, Yazici Gonca, Cagatay Penbe, Ciftci Cavlan*

**010**

## THE INTERRELATIONSHIP BETWEEN KLOTHO GENE POLYMORPHISM G-395A AND LEFT VENTRICULAR HYPERTROPHY IN HEMODIALYSIS PATIENTS

*Cvetkovic Tatjana, Apostolovic Branslav, Stefanovic Nikola, Pavlovic Dusica, Cvetkovic Mina, Petkovic Igor, Pavlovic Dimitrije, Mitic Branka*

**011**

## INVESTIGATION OF THE EFFECT OF HUMAN GENETIC VARIATIONS ON THE OUTCOME (TDM) OF VORICONAZOLE TREATMENT IN PEDIATRIC CANCER PATIENTS

*Saeed Dina, Shalaby Lobna, Nagy Mohamed, ElZeiny Ahmed, Mostafa Tarek M., ElRakaiby Marwa T., Nooh Mohammed M., El-Haddad Alaa, Abbassi Maggie, Aziz Ramy K.*

# CYP2D6 GENOTYPING EXPERT ANALYSES

**012**

## CYP2D6 GENOTYPE-PHENOTYPE ANALYSIS BASED ON POPULATION PHARMACOKINETIC MODELLING OF VORTIOXETINE

*Frederiksen Trine, Areberg Johan, Ellen Schmidt, Bjerregaard Stage Tore, Brøsen Kim*

**013**

## CYTOCHROME P450 2D6 \*3, \*4, \*6 AND \*41 ALLELE SPECIFIC COPY NUMBER DETERMINATION IN CYP2D6XN SAMPLES USING DDPCR

*de Jonge Evert, Matic Maja, van Schaik Ron*

**014**

## THE ROLE OF RISKY POLYMORPHIC VARIANTS OF CYP2D6 GENE IN THE EFFICACY OF VALPROIC ACID THERAPY IN PATIENTS WITH EPILEPSY

*Zobova Svetlana, Dmitrenko Diana, Shnayder Natalia, Prusova Tatiana, Yakovleva Kristina, Pravdin Denis, Yakimova Yana*

# DECISION SUPPORT TOOLS

**015**

DO CYP3A4\*20 AND CYP3A4\*22 ALLELES AFFECT THE PHARMACOKINETIC PARAMETERS OF CYP3A4 SUBSTRATES?

*Saiz-Rodríguez Miriam, Ochoa Dolores, Belmonte Carmen, Román Manuel, Zubiaur Pablo, Santos María, Rodríguez-Antona Cristina, Abad-Santos Francisco*

**016**

IMPLEMENTATION OF CLINICAL DECISION SUPPORT SYSTEM FOR DOSING IN PSYCHOPHARMACOTHERAPY IN PATIENTS WITH AFFECTIVE DISORDERS BASED ON THE PHARMACOGENOMIC MARKERS

*Mikhail Zastrozhin, Valentin Skryabin, Evgeny Bryun, Alexander Sorokin, Dmitry Sychev*

**017**

LEVERAGING GLOBAL TECH TO PUT IOT TO WORK FOR CARE TEAMS

*Lunzenfichter Gilles*

**018**

IBERIAN DATABASE BUILDING OF PHARMACOGENETIC INDICATORS, ACCORDING TO THE INFORMATION PRESENT IN THE SUMMARY OF DRUG CHARACTERISTICS AVAILABLE IN PORTUGAL AND SPAIN

*Advinha Ana Margarida, Cachão Rita de Oliveir, Alípio Carolina, Correia Catarina, Martins-Vaz Rita, André Francisco, Gonçalves Rui, De Andrés Fernando, Llerena-Ruiz Ádrian, Lopes Manuel José*

# DIABETES

**019**

EVALUATION OF NOVEL ADIPOKINES (OMENTIN-1, APELIN AND CHEMERIN) AS POTENTIAL BIOMARKERS OF PRESENCE AND SEVERITY OF DIABETIC RETINOPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS

*Yasir Md, Senthilkumar Gp*

**020**

EVALUATION OF THE SUITABILITY OF NINETEEN PHARMACOGENOMICS BIOMARKERS FOR INDIVIDUALIZED METFORMIN THERAPY FOR TYPE 2 DIABETES PATIENTS

*Khakaza L, Masilela C, Pearce B, October Z, Johnson R, Adeniyi OV, Ongole JJ, Benjeddou Mongi*

**021**

FREQUENCY OF CYP2C9 (\*2, \*3 AND IVS8-109A>T) ALLELIC VARIANTS AND THEIR CLINICAL IMPLICATIONS AMONG MEXICAN PATIENTS WITH DIABETES MELLITUS TYPE 2 UNDERGOING TREATMENT WITH GLIBENCLAMIDE AND METFORMIN

*Cuautle Rodríguez Patricia, Rodríguez Rivera Nidia, De Andrés Fernando, Castillo Nájera Fernando, Llerena Adrián, Molina Guarneros Juan Arcadio*

**022**

**METFORMIN PHARMACOKINETICS IN JORDANIANS: EFFECTS OF ORGANIC CATIONS TRANSPORTERS**

*Hakooz Nancy, Jarrar Yazun Bashir, Zihlif Malik, Imraish Amer, Arafat Arafat, Hamed Saja*

**023**

**STUDY OF THE GENETIC POLYMORPHISM OF THE SLC22A1, SLC22A2 AND SLC22A3 GENES AMONG ECUADORIAN DIABETES MELLITUS TYPE 2 PATIENTS**

*Terán Enrique, Dorado Pedro, De Andrés Fernando, Bonilla Mauro, Tana Leandro, Mora Lorena, Estévez María, Llerena Adrián*

**024**

**TAILORING TYPE II DIABETES TREATMENT: 5-HTTLPR AND VNTR STIN2 POLYMORPHISM AND METFORMIN EFFICACY**

*Ochi Taichi, Denig Petra, Heerspink Hiddo, Hak Eelko, Willfert Bob*

## **DRUG TRANSPORTERS**

**025**

**EFFECTS OF ABCB1 GENETICS VARIANT ON TACROLIMUS PHARMACOKINETICS IN ALGERIAN ADULT KIDNEY TRANSPLANT PATIENTS**

*Bouhrara Wefa, Boudia Fatma, Aberkane Meriem, Moghtit Fatima Zohra, Toumi Houari*

**026**

**FDA APPROVED CLINICALLY USED DRUGS AS BREAST CANCER RESISTANCE PROTEIN INHIBITORS**

*Deng Feng, Kidron Heidi, Niemi Mikko*

## **GENOTYPING PLATFORMS**

**027**

**COPY NUMBER VARIATION ASSOCIATED WITH ANTI-TNF RESPONSE AND THE APPEARANCE OF PARADOXICAL PSORIASIFORM REACTIONS IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS**

*Ovejero-Benito María Carmen, Sanz-García Ancor, Hevia Laura, Reolid Alejandra, Muñoz-Aceituno Ester, Llamas-Velasco Mar, Navarro Raquel, Abad-Santos Francisco, Daudén Esteban*

**028**

**EFFECTS OF CES1 GENE POLYMORPHISM ON ANTIPLATELET EFFECT OF RECEPTOR P2Y12 BLOCKER CLOPIDOGREL**

*Osipova Darya, Mirzaev Karin, Sychev Dmitry*

# LUNG CANCER

**029**

IDENTIFICATION OF BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ERLOTINIB AND AFATINIB

*Svedberg Anna, Vikingsson Svante, Vikström Anders, Hornstra Niels, Kentson Magnus, Brandén Eva, Koyi Hirsh, Bergman Bengt, Green Henrik*

**030**

WHOLE-EXOME SEQUENCING ASSOCIATES' GENETIC VARIATION IN HEMATOPOIESIS PATHWAYS WITH GEMCITABINE/CARBOPLATIN-INDUCED THROMBOCYTOPENIA

*Björn Niclas, Sigurgeirsson Benjamin, Svedberg Anna, Pradhananga Sailendra, Brandén Eva, Koyi Hirsh, Lewensohn Rolf, De Petris Luigi, Apellániz-Ruiz Maria, Rodríguez-Antona Cristina, Lundeberg Joakim, Gréen Henrik*

# ONCOLOGY

**031**

GENOTYPING OF THE DPYD GENE. INITIATIVE TURNED INTO REALITY

*Comes Raga Ana, Guzmán Luján Carola, Guallart Noguera Cristina, Ferriz Vivancos Jorge, Ávila Andrade Claudio, Camps Herrero Carlos, Guaita Martínez Marcos, Marcaida Benito Goitzane, Ferrer Bolufer Irene*

**032**

A RARE DPYD VARIANT (C.257C>T) ALTERS ENZYME ACTIVITY AND IS ASSOCIATED WITH SEVERE CAPECITABINE TOXICITY

*García-González Xandra, Abarca Judith, Kaczmarcyk Bartosz, Salvador-Martin Sara, García-Alfonso Pilar, Revuelta-Herrero Jose Luis, Marzal-Alfaro Belén, Sanjurjo-Sáez María, López-Fernández Luis Andrés*

**033**

ADVANCED RENAL CANCER PATIENTS WITH TUMOR MUTATIONS IN PBRM1 AND KDM5C SHOW IMPROVED RESPONSE TO ANTI-ANGIOGENIC THERAPY

*Santos María, Lanillos Javier, Roldán-Romero Juan María, Calsina Bruna, Pulgarín Marta, Martínez Ángel, Letón Rocío, Montero-Conde Cristina, Cascón Alberto, Robledo Mercedes, Beuselinck Benoit, Rodríguez-Antona Cristina, García-Donas Jesús*

**034**

ASSOCIATION OF RISKY POLYMORPHIC VARIANTS OF OPRM1 GENE WITH THE EFFECTIVENESS OF PAIN THERAPY IN PATIENTS WITH PANCREATIC MALIGNANT NEOPLASMS

*Bobrova Olga, Dmitrenko Diana, Zobova Svetlana, Yakimova Yana, Shnayder Natalia*

**035**

BENEFITS OF NEXT GENERATION SEQUENCING IN THE SCREENING OF DPD DEFICIENCY

*Larrue Romain, Hennart Benjamin, Broly Franck*

**036**

**GERMLINE BIOMARKERS GUIDING DOCETAXEL TREATMENT OF PROSTATE CANCER**

*Varnai Reka, Koskinen Leena M, Mäntylä Laura E, Szabo Istvan, FitzGerald Liesel M, Sipeky Csilla*

**037**

**HLA-G & CADHERIN PROFILE EXPRESSION, AND ITS PROGNOSTIC VALUE IN RENAL CELL CARCINOMA.**

*Concha Mayayo Julia, Garcia García Cristina Belen, Sánchez Zalabardo Jose Manuel, López de Val Alejandro, Ribate Molina Maria Pilar, Gomez Barrera Manuel, Saez Gutierrez Berta*

**038**

**OUTCOME DEFINITION INFLUENCES THE RELATIONSHIP BETWEEN GENETIC POLYMORPHISMS OF ERCC1, ERCC2, SLC22A2 AND CISPLATIN NEPHROTOXICITY IN ADULT TESTICULAR CANCER PATIENTS**

*Zazuli Zulfan, Otten Leila S., Drögemöller Britt I., Medeiros Mara, Wright Galen E.B., Vijverberg Susanne J.H., Masereeuw Rosalinde, Roos Colin J.D., Liu Geoffrey, Carleton Bruce C., Maitland-van der Zee Anke H.*

**039**

**PTEN EXPRESSION AND MUTATIONS IN TSC1, TSC2 AND MTOR ARE ASSOCIATED WITH RESPONSE TO RAPALOGS IN PATIENTS WITH RENAL CELL CARCINOMA.**

*Roldán Romero Juan María, Beuselinck Benoit, Santos María, Rodriguez-Moreno Juan Francisco, Lanillos Javier, Calsina Bruna, Gutierrez Ana, Tang Karin, Lainez Nuria, Puente Javier, Castellano Daniel, Climent Miguel A, Esteban Emilio, Arranz Jose A, Marteen Albersen, Ouda*

**040**

**THE SINGLE NUCLEOTIDE POLYMORPHISM RS7121 IN THE GENE GNAS AS A BIOMARKER FOR TUMOR PROGRESSION AND POOR SURVIVAL IN CANCER PATIENTS**

*Möhlendick Birte, Ting Saskia, Schmid Kurt Werner, Siffert Winfried*

**041**

**WHAT TO GENOTYPE TO PREDICT FLUOROPYRIMIDINES TOXICITY - POSSIBLE ROLE OF DPYD 496A>G VARIANT**

*Ganoci Lana, Simicevic Livija, Bilic Ivan, Bozina Tamara, Bozina Nada*

**042**

**THE ASSOCIATION OF SINGLE-NUCLEOTIDE POLYMORPHISMS WITH EFFICACY AND TOXICITY OF CABAZITAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**

*de With Mirjam, Belderbos Bodine PS, Singh Rajbir K, Agema Bram C, El Bouazzaoui Samira, Oomen-de Hoop Esther, de Wit Ronald, van Schaik Ron HN, Mathijssen Ron HJ, Bins Sander*

**043**

**BIOMARKERS AND TUMOR AGGRESSIVENESS**

*Topolcan Ondrej, Kucera Radek, Karlikova Marie, Svobodova Sarka, Simanek Vaclav, Dolejsova Olga, Hora Milan, Finek Jindrich, Treska Vladislav*



**044**

#### BIOBANKS USE IN ONCOLOGY RESEARCH

*Topolcan Ondrej, Karlikova Marie, Kucera Radek, Kinkorova Judita, Simanek Vaclav, Racek Jaroslav, Svobodova Sarka*

**045**

#### EFFECTS OF PHARMACOGENETIC VARIANTS ON VEMURAFENIB-RELATED TOXICITIES IN PATIENTS WITH MELANOMA

*de With Mirjam, Goey Andrew KL, Mathijssen Ron HJ, Singh Rajbir K, Agema Bram C, Oomen-de Hoop Esther, van der Veldt Astrid AM, van Schaik Ron HN, Bins Sander*

**046**

#### ASSOCIATION BETWEEN ABCB1 GENETIC VARIANTS AND PERSISTENT CHEMOTHERAPY-INDUCED ALOPECIA IN BREAST CANCER PATIENTS TREATED WITH DOCETAXEL

*Nunez-Torres Rocio, Rodrigo-Faus Maria, Tejera-Perez Hugo, Pita Guillermo, del Monte-Millan Maria, Herrera Belen, Bermejo Begoña, Lluch Anna, Martin Miguel, Gonzalez-Neira Anna*

## PAIN

**047**

#### ASSOCIATION OF RISKY POLYMORPHIC VARIANTS OF OPRM1 GENE WITH THE EFFECTIVENESS OF PAIN THERAPY IN PATIENTS WITH PANCREATIC MALIGNANT NEOPLASMS

*Bobrova Olga, Dmitrenko Diana, Zobova Svetlana, Shnayder Natalia, Yakimova Yana, Prusova Tatiana*

**048**

#### GENETIC CASE-CONTROL ASSOCIATION STUDY OF METAMIZOLE-INDUCED AGRANULOCYTOSIS

*Cismaru Anca Liliana, Rudin Deborah, Ibañez Luisa, Liakoni Evangelina, Kreutz Rheinhold, Carvajal Alfonso, Lucena M. Isabel, Martin Javier, Sancho Ponce Esther, Ericsson Niclas, Molokhia Mariam, collaborators E U D A C, Largiadèr Carlo, Haschke Manuel, Hallberg Pär, Wade*

**049**

#### IDENTIFICATION OF GENETIC DETERMINANTS FOR CENTRAL PAIN SENSITIZATION IN FIBROMYALGIA PATIENTS

*Gloor Yvonne, Mouterde Médéric, Matthey Alain, Poloni Estella S., Chabert Jocelyne, Simona Aurélien, Bovet Luc, Besson Marie, Piguet Valérie, Cedraschi Christine, Pickering Gisèle, Kosek Eva, Ehret Georg, Desmeules Jules*

**050**

#### PHARMACOGENETICS APPLIED TO TAPENTADOL EFFECTIVENESS ON AMBULATORY CHRONIC PAIN PATIENTS

*Barrachina Bernabeu Jordi, Muriel Serrano Javier, Margarit Ferri Cesar, Ballester Pura, López-Gil Santiago, López-Gil Vicente, del Barco Guillermo, Flor Andrea, Morales Domingo, Peiró Ana María*

**051**

**TRAMADOL FROM CYP2D6 PHARMACOGENETIC TESTING TO CLINICAL DATA**

*Cevik Mehtap, Karaalp Atila, Gunduz Hakan, Yazici Gonca, Cagatay Penbe, Susleyici Belgin*

**052**

**ULTRA-RAPID CYP2D6-METABOLIC PHENOTYPE INFLUENCE ON CHRONIC NON-CANCER PAIN PATIENTS WITH PRESCRIPTION OPIOID USE DISORDER**

*Muriel Javier, del Barco Guillermo, Barrachina Jordi, Margarit César, Planelles Beatriz, Inda María del Mar, Morales Domingo, Peiró Ana María*

## **PATIENT PERSPECTIVES**

**053**

**PREDICTION OF TOXICITY A METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED MODERATE-SEVERE PSORIASIS**

*Membrive Cristina, Pérez Ramírez Cristina, Maldonado Montoro María del Mar, Jiménez Puerta Gonzalo, Arias Santiago Salvador, Jiménez Morales Alberto*

## **PEDIATRIC HEMATO-ONCOLOGY**

**054**

**MIRNA-PHARMACOGENOMICS FOR THE PREDICTION OF OUTCOME IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

*Gutierrez-Camino Angela, Artetxe Aizpea, Santos-Zorrozua Borja, Martin-Guerrero Idoia, Garcia de Andoin Nagore, Sastre Ana, Astigarraga Itziar, Lopez-Lopez Elixabet, Garcia-Orad Africa*

**055**

**PHARMACOGENETICS OF CHEMOTHERAPY RESPONSE IN OSTEOSARCOMA: A GENETIC VARIANT IN SLC7A8 IS ASSOCIATED WITH PROGRESSIVE DISEASE**

*Hurkmans Evelien, Vos Hanneke, Groothuismink Johanne, van der Graaf Winette, Flucke Uta, Schreuder Bart, Hagleitner Melanie, Gelderblom Hans, van der Straaten Tahar, Bovée Judith, Cleton-Janssen Anne-Marie, de Bont Eveline, Bras Johannes, Caron Huib, Windsor Rachael, Wh*

**056**

**PREDICTIVE POLYMORPHISMS OF THE EFFICACY OF THE INDUCTION CHEMOTHERAPY TREATMENT IN NEUROBLASTOMA**

*Olivera Gladys, Yáñez Yania, Herrero María José, Berlanga Pablo, Gargallo Pablo, Sendra Luis, Hervás David, Font de Mora Jaime, Segura Vanesa, Ramal Desiré, Fernández-Delgado Rafael, Castel Victoria, Cañete Adela, Aliño Salvador Francisco*

## PGX AND EMA/FDA REGULATORY ASPECTS

**057**

GENE SIGNATURES OF EARLY RESPONSE TO ANTI-TNF DRUGS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE

*Salvador Martín Sara, Raposo Irene, Navas Víctor Manuel, Rodríguez Alejandro, Gonzalez Rafael, Sánchez Cesar, Tolín Mar, Pujol-Muncunill Gemma, Bossacoma Ferrán, Moreno Ana, Magallares Lorena, Fobelo María José, Millán Antonio, Eizaguirre Javier, Blanca José Antonio, Benguria Alberto, Vazquez Enrique, Dopazo Ana, Abarca Judith, García-González Xandra, Sanjurjo María, Lopez-Fernandez Luis A.*

**058**

PHARMACOGENOMIC PROFILING OF HUMAN DRUG TARGETS – TOWARDS TRANSLATING GENETIC VARIATION INTO PERSONALIZED PRESCRIBING

*Zhou Yitian, Lauschke Volker Martin*

**059**

ROLE OF TLR2 DNA VARIANTS AS MARKERS OF RESPONSE TO ANTI-TNF TREATMENT IN INFLAMMATORY BOWEL DISEASE

*Abarca Zabala Judith, Salvador-Martín Sara, Pujol-Muncunill Gemma, Bossacoma Ferrán, Navas Victor, Viada Francisco J, Muñoz Rosana, Moreno Ana, Magallares Lorena, Clemente Susana, Segarra Oscar, Rodríguez Alejandro, Loverdos Ines, Merino-Bohorquez Vicente, Cuadrado Ca*

**060**

PHARMACOGENOMICS OF STATIN-RELATED MYOPATHY (SRM): A CASE REPORT

*Esquivel Bernard, Juginovic Alen, Mikula Ivan, Primorac Dragan, Donaldson Morgan*

**061**

PHARMACOGENOMIC GUIDED THERAPY IN PATIENT WITH MAJOR DEPRESSIVE DISORDER

*Juginovic Alen, OneOme, Mikula Ivan, Primorac Dragan, Donaldson Morgan, Esquivel Bernard*

## PSYCHIATRY

**062**

A ONE-YEAR LONGITUDINAL FOLLOW-UP STUDY OF TREATMENT COMPLIANT SUICIDE SURVIVORS: TRACKING THE RELATION BETWEEN COMBINED CYP2D6-CYP2C9 METABOLIC CAPACITY WITH PHARMACOTHERAPY AND SUICIDE REATTEMPTS

*Peñas-Lledó Eva M., Guillaume Sebastien, De Andrés Fernando, Fariñas Humberto, Kahn Jean P., Leboyer Marion, Llerena Adrián, Courtet Philippe*

**063**

ASSOCIATION BETWEEN DRUG-GENE-INTERACTION, DRUG-DRUG-INTERACTION, AND DRUG-DRUG-GENE-INTERACTION AND EARLY DISCONTINUATION, SWITCHING AND DOSE ADJUSTMENT OF (ES) CITALOPRAM: AN EXPLORATIVE STUDY.

*Bahar Muh. Akbar, Lanting Pauline, Bos Jens H.J., Sijmons Rolf H., Hak Eelko, Wilffert Bob*

**064**

ASSOCIATION OF ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SYNDROME WITH POLYMORPHISM RS1800955 OF DRD4 GENE PROMOTER

*Vaiman Elena, Moskaleva Polina, Shnayder Natalia, Nasyrova Regina*

**065**

ASSOCIATION OF AUTISM SPECTRUM DISORDER WITH THE DIFFERENT GENETIC BIOMARKERS IN THE BANGLADESHI CHILDREN

*Islam Mohammad Safiqul, Sen Niloy, Uddin Md. Giash, Uddin Md. Sarowar, Siddiqui Shafayet Ahmed, Hussain Md. Saddam, Millat Md. Shalahuddin*

**066**

CYP2D6 GENOTYPE, GENETIC ANCESTRY AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE EFFECTS IN CUBAN PATIENTS WITH SCHIZOPHRENIA

*Roblejo Balbuena Hilda, Marcheco Teruel Beatriz, González Pal Salvador, Monzón Benítez Giselle, Marín Padrón Lilia C, De Andrés Fernando, Llerena Adrián*

**067**

CYP2D6 POLYPORPHISM, POLYPHARMACY AND SEVERE ANTIDEPRESSANT DRUG REACTIONS

*Peñas-Lledó Eva M., Martín Reyes Migdyrai, De Andrés Fernando, Llerena Adrián*

**068**

DEVELOPING OF NON-INVASIVE PROTOCOL TO DETERMINE NON-STRESSED AND STRESSED STATE USING "METABOLOMIC FOOTPRINT" BY DIRECT INFUSION MASS SPECTROMETRY.

*Lorenzo-Tejedor Mónica, Goñi Guillermina, De la Cámara Concepción, Bailón Raquel, Aguiló Jordi, Maria Luisa Bernal*

**069**

EFFECTS OF CYP3A4 GENETIC POLYMORPHISM ON THE EFFICACY AND SAFETY OF DIAZEPAM IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME

*Skriabin Valentin, Zastrozhin Mikhail, Bryun Evgeny, Sychev Dmitry*

**070**

GENETIC POLYMORPHISMS OF KDR ARE NOT ASSOCIATED WITH MAJOR DEPRESSION

*Nunes Fernanda, Ferezin Letícia, Pereira Sherliane, Menezes Itiana, Baes Cristiane, Juruena Mário, Lacchini Riccardo*

**071**

INTERPLAY OF CYP2D6, ABCB1 AND ABCG2 POLYMORPHISMS – EFFECT ON EXPOSURE, EFFICACY AND SAFETY OF LONG-ACTING RISPERIDONE IN SCHIZOPHRENIA PATIENTS

*Ganoci Lana, Živković Maja, Trkulja Vladimir, Božina Tamara, Šagud Marina, Lovrić Mila, Božina Nada*

**072**

PHARMACOGENETICS AND THERAPEUTIC DRUG MONITORING APPLICATION IN A CLOZAPINE PATIENT.

*Sangüesa Sangüesa Estela, Concha Mayayo Julia, Cirujeda Christine, Padilla Pedro Pablo, Ribate Molina Maria Pilar, Garcia Garcia Cristina Belen*

**073**

PHARMACOGENETICS OF BENZODIAZEPINE TRANQUILIZER PHENAZEPAM: COMBINATORIAL ANALYSIS OF CYP450 AND P-GLYCOPROTEIN GENETIC POLYMORPHISMS

*Tereshchenko Olesya, Ivashchenko Dmitriy, Temirbulatov Ilyas, Grishina Elena, Sychev Dmitriy*

**074**

WHAT IS BETTER: CONDUCTING PHARMACOGENETIC STUDIES BEFORE OR AFTER THE DEVELOPMENT OF ADVERSE DRUG REACTIONS?

*Moskaleva Polina, Vaiman Elena, Bochanova Elena, Shnayder Natalia, Nasyrova Regina*

## SOLID ORGAN TRANSPLANTATION

**075**

GENETIC VARIABILITY OF ENZYMES AND TRANSPORTERS WITH KEY-ROLE IN PHARMACOKINETICS OF CYCLOSPORINE AND TACROLIMUS-ANALYSIS OF DATA PUBLISHED FOR TRANSPLANTED PATIENTS FROM SERBIA

*Beletic Andjelo, Tijanic Aleksandra, Stankovic Sanja*

**076**

PROCALCITONIN'S ROLE FOR PNEUMONIA DIAGNOSIS IN LUNG TRANSPLANT PATIENTS READMITTED TO INTENSIVE CARE UNIT

*Tejada Sofia, Mazo Christopher, Romero Anabel, Peña Yolanda, Pont Teresa, Rello Jordi*

**077**

THE INFLUENCE OF TACROLIMUS INTRAINDIVIDUAL VARIABILITY AND CYP3A5 GENE POLYMORPHISM ON KIDNEY FUNCTION IN LATE PERIOD AFTER KIDNEY TRANSPLANTATION

*Stefanovic Nikola, Cvetkovic Tatjana, Velickovic-Radovanovic Radmila, Mitic Branka, Damnjanovic Ivana, Catic-Djordjevic Aleksandra, Pavlovic Dusica*

**078**

THE USE OF PHARMACOGENETICS AS A TOOL TO IMPROVE THE INDIVIDUAL IMMUNOSUPPRESSIVE PHARMACOTHERAPY AND KNOWLEDGE OF AN ASSOCIATION OF TRANSPLANTED HEPATIC PATIENTS.

*Concha Mayayo Julia, Sangüesa Sangüesa Estela, Saez Gutierrez Berta, Garcia Garcia Cristina Belen, Ribate Molina Maria Pilar*

## OTHER

### 079

ASSESSMENT OF THE PHENOTYPIC IMPACT OF DPYD POLYMORPHISMS C.85C>T, C.496A>G, AND 1601G>A IN HEALTHY BLOOD DONORS.

*Hamzic Seid, Schärer Dominic, Ramette Alban, Fontana Stefano, Amstutz Ursula, Largiadèr Carlo*

### 080

ASSOCIATION BETWEEN CTLA4, CD80 AND CD86 GENE POLYMORPHISMS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT

*Márquez Pete Noelia, Pérez Ramírez Cristina, Maldonado Montoro María del Mar, Cáliz Cáliz Rafael, Jiménez Morales Alberto*

### 081

ASSOCIATION BETWEEN HLA-DQA1-HLA-DRB1 VARIANT RS2647087 AND THIOPURINE INDUCED PANCREATITIS.

*Nielen Suzanne, Broekman Mark, van Marrewijk Corine, Guchelaar Henk-Jan, de Jong Dirk, Coenen Marieke*

### 082

ASSOCIATION OF THE PTGS1 POLYMORPHISM AND THE OCCURRENCE OF UPPER GASTROINTESTINAL BLEEDING (UGIB).

*Forgerini Marcela, de Nadai Tales Rubens, Urbano Gustavo, Herdeiro Maria Teresa, Figueiras Adolfo Guzman, Cachafeiro Maruxa Zapata, Mastroianni Patrícia de Carvalho*

### 083

DEPENDENCE OF MICROBIOTA ANALYSIS ON THE 16S RRNA TARGET REGION

*Borro Marina, Gentile Giovanna, Simmaco Maurizio*

### 084

EFFECT OF CYP3A5\*3 POLYMORPHISM ON ANTI-INFLAMMATORY THERAPY IN CHILDREN WITH BRONCHIAL ASTHMA

*Zastrozhina Anastasiya, Sychev Dmitry*

### 085

EFFECT OF POLYMORPHISMS IN VKORC1 AND CYP2C9 VARIANTS ON ACENOCOUMAROL MAINTENANCE DOSE, STROKE RECURRENCE AND BLEEDING EVENTS USING A GENOME-WIDE ASSOCIATION STUDY

*Cullell Natalia, Carrera Caty, Muiño Elena, González-Sánchez Jonathan, Molina Jessica, Besora Sarah, Sotoca Javier, Giral Eva, Jiménez-Conde Jordi, Cabezas Juan Antonio, Montaner Joan, Prats-Sanchez Luis, Camps-Renom Pol, Purroy Francisco, Tur Silvia, Lopez-Cancio Elen*

**086**

**ENHANCING PRECISION MEDICINE THROUGH CLINICAL MASS SPECTROMETRY PLATFORM**

*Svinarov Dobrin*

**087**

**GENOMIC ANCESTRY, CYP2D6, CYP2C9 AND CYP2C19 AMONG LATIN-AMERICANS**

*Rodrigues Soares Fernanda, Peñas-Lledó Eva M., De Andrés Fernando, Tarazona Santos Eduardo, Sosa Macías Martha, Terán Enrique, López López Marisol, Rodeiro Idania, Moya Graciela E., Calzadilla Luis R., Ramírez Roa Ronald, Grazina Manuela, Estévez-Carrizo Francisco E.*

**088**

**HCP5 RS2395029: A RAPID AND INEXPENSIVE ALTERNATIVE TO HLA-B\*57:01 GENOTYPING TO PREDICT THE ABACAVIR HYPERSENSITIVITY REACTION (ABC-HSR) IN IBERIANS.**

*Zubiaur Pablo, Saiz-Rodriguez Miriam, Villapalos Gonzalo, Navares-Gómez Marcos, Abad-Santos Francisco*

**089**

**IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF CYP4V2 GENETIC VARIANTS EXHIBITING DECREASED ACTIVITY OF LAURIC ACID METABOLISM**

*Lee Su-Jun, Jarrar Yazun, Shin Jae-Gook*

**090**

**PERCEPTION OF PHARMACY STUDENTS TOWARD PHARMACOGENOMIC KNOWLEDGE AND ATTITUDE AMONG DIFFERENT UNIVERSITIES IN JORDAN AND WEST BANK OF PALESTINE**

*Jarrar Yazun, Rami Musleh, Mohamad Hawash, Jarrar Qais*

**091**

**PHARMACOGENETIC CHARACTERISATION OF THE EMPAR COHORT**

*Stingl Julia, Haenisch Britta, Linder Roland, Langner Daria, Garling Marco, Roethlein Christoph, Gomm Willy, Heß Steffen, Steffens Michael, Hübner Tatjana, Fracowiak Jochen*

**092**

**PHARMACOGENETICALLY RELEVANT VARIANTS IN THE AZORES ISLANDS (PORTUGAL)**

*Pereirinha Tânia, Bulhões Sara, Brilhante Maria José, Mota-Vieira Luísa, Castelo Branco Claudia*

**093**

**PHARMACOGENETICS OF DRUG-GENE INTERACTION AND DRUG-DRUG-GENE INTERACTION IN ELDERLY PEOPLE: A PILOT STUDY ON CYP2C9 AND CYP2C19**

*Verde Zoraida, García-Aldea Sara, Rodríguez-Díez Jose Andrés, Velasco Verónica, Fernández-Araque Ana*

**094**

**POLYMORPHISMS OF PIK3CA ARE NOT ASSOCIATED WITH THE RISK FOR ERECTILE DYSFUNCTION**

*Perticarrara Ferezin Letícia, Heiji Lima Miyazaki Anderson, Fernandes Molina Carlos Augusto, Ferreira de Andrade Murilo, Tucci Jr. Silvio, Hirsch Emilio, Tanus-Santos José Eduardo, Lacchini Riccardo*

**095**

**RELATIONSHIP BETWEEN CYP1A2, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4 METABOLIC PHENOTYPE AND GENOTYPE IN THE NICARAGUAN MESTIZO POPULATION**

*De Andrés Fernando, Altamirano Tinoco Catalina, Ramírez-Roa Ronald, Montes Mondragón Carlos, Arias Zepeda Ariel, Dorado Pedro, Castellano Cisneros Efrén, Peñas-Lledó Eva M., Llerena Adrián*

**096**

**TRANSCRIPTOMIC ANALYSIS OF CHRONIC IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG.**

*Hernández-Sánchez Jesús María, Bastida José María, Alonso-López Diego, Benito Rocío, González-Porras José Ramón, De las Rivas Javier, Hernández Rivas Jesús María, Rodríguez-Vicente Ana Eugeni*

**097**

**PHENYTOIN ADVERSE REACTION IN A CHILD WITH DEFECTIVE CYP2C9. A CASE REPORT IN PEDIATRIC INTENSIVE CARE UNIT**

*Cocciadiferro Dario, Agolini Emanuele, Marano Marco, Nicoletti Ferdinando, Pro Stefano, Goffredo Bianca Maria, Novelli Antonio*

**098**

**GLOBAL OUTLOOK ON PHARMACOGENOMICS EDUCATION**

*Karas Kuzelicki Natasa, Prodan Žitnik Irena, Gurwitz David, Llerena Adrian, Cascorbi Ingolf, Siest Sofia, Simmaco Maurizio, Ansari Marc, Pazzagli Mario, Di Resta Chiara, Brandslund Ivan, Schwab Matthias, Vermeersch Pieter, Lunshof Jeantine E., Flordellis Christodoulos S., Dedoussis George, Fuhr Uwe, Stingl Julia C., van Schaik Ron H.N., Manolopoulos Vangelis G., Marc Janja*

**099**

**INSIGHTS INTO THE BIOLOGICAL ROLE OF THIOPURINE S-METHYLTRANSFERASE**

*Smid Alenka, Urbancic Dunja, Kotar Anita, Plavec Janez, Mlinaric-Rascan Irena*

**100**

**GENOME-WIDE STUDY IDENTIFIES ASSOCIATION BETWEEN HLA-B\*55:01 AND PENICILLIN ALLERGY USING ELECTRONIC HEALTH RECORDS OF BIOBANK PARTICIPANTS**

*Krebs Kristi, Lepamets Maarja, Bovijn Jonas, Censis Jenny, Lindgren Cecilia, Holmes Michael, Mägi Reedik, Milani Lili, Fadista João*



# The world's largest collection of SNP genotyping assays

Prepare to launch into your next discovery



We have expanded our menu of Applied Biosystems™ TaqMan® SNP Genotyping Assays, and we now offer **over 17 million predesigned assays** for your convenience. With this expansion, the SNP you want is now more likely to be available.

Gain the confidence you deserve with this updated collection of TaqMan Assays, the gold-standard technology in genotyping and genetic variation analysis.



- A rigorous pipeline with over 90 parameters to design the optimal primer and probe combinations with the specificity you need
- Functional quality testing on at least 20 samples of gDNA for each assay
- Flexible formats to accommodate any number of targets and samples

- Proven technology, backed by over 40,000 publications and over 300 patents
- Guaranteed performance\*—if a TaqMan Assay does not perform according to specifications, we'll replace it at no cost or credit your account

Check out the updated web experience with the TaqMan Assays search page.

Web ordering just got easier with our new search tool, expanded assay content, and publication references. Additional collections such as DME assays and a custom TaqMan Assay Design Tool are also available.

\* To see the full guarantee, go to [thermofisher.com/taqmanguarantee](http://thermofisher.com/taqmanguarantee).

Find your assay at [thermofisher.com/taqman](http://thermofisher.com/taqman)

**For Research Use Only. Not for use in diagnostic procedures.** © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under permission and license. **COL17018 0818**

**ThermoFisher**  
SCIENTIFIC

# GENERAL INFO

## CONGRESS VENUE

NH HOTEL COLLECTION SEVILLA

Avda. Diego Martínez Barrio, 8 - 41013 Sevilla SPAIN

<https://www.nh-hotels.com/hotel/nh-collection-sevilla>



## POSTER EVALUATION

During the Conference posters will be displayed, divided by topic.

The Poster Evaluation Committee will vote the best one and the Winner will be announced on Thursday 17th at the end of the scientific sessions.

The winning poster will be posted on [www.2019ESPTcongress.eu](http://www.2019ESPTcongress.eu)

## WI-FI CONNECTION

Wi-Fi connection will be available in the whole building; no password needed.

## OFFICIAL LANGUAGE

All lectures will be in English.

## CONGRESS DINNER

*(not included in the registration fee)*

The Congress Dinner will be held on Thursday, October 17<sup>th</sup> at restaurant **ABEDES TRIANA**

Address: Calle Betis 69, Seville *(it is about 3 Km away from the congress venue, not walking distance)*

- Reduced fee € 50,00 per person
- Accompanying persons and exhibitors € 60,00 per person

# SPONSORS

## PLATINUM SPONSORS



## GOLD SPONSORS



## SILVER SPONSORS





## BRONZE SPONSORS



## OTHER SPONSOR





**ESPT**

European Society of Pharmacogenomics and Personalised Therapy  
*A Scientific Society for Individualised Medicine*

## ESPT EXECUTIVE OFFICE

---

Marina Festinese  
Via Carlo Farini 81  
20159 Milano (Italy)  
Tel. +39 0266802323-959  
office@esptsociety.eu  
www.esptsociety.eu



**MZ**

**CONGRESSI**

## ORGANISING SECRETARIAT

---

MZ Congressi srl - Via C. Farini, 81  
20159 Milano (Italy)  
Tel. +39 02 66802323  
Fax +39 02 6686699  
info@2019ESPTcongress.eu  
www.mzcongressi.com